Draba nemorosa
Draba nemorosa
Draba nemorosa, a perennial plant native to Europe and Asia, has not been traditionally used in any known medical practices. Scientific studies have shown that Xinyin tablets containing extracts from Draba nemorosa may potentially alleviate chronic heart failure in mice by regulating the HDAC3-PINK1/Parkin signaling pathway; however, these findings are preliminary and require further human trials for confirmation. Additionally, a study indicated that Draba nemorosa var. hebecarpa demonstrated moderate antitumor activity in vitro, comparable to some mushroom extracts, though this finding is also early-stage and needs more research. Psychrotolerant bacterial isolates from cold-adapted plants, including potentially those from Draba nemorosa, were found to improve the cold resistance of bean seedlings by reducing freezing injury and oxidative stress, suggesting potential applications in agriculture but not yet in medicine. No major safety concerns have been recorded for this plant. There are currently no reported drug interactions associated with Draba nemorosa.
- Best evidence
- D
- Cautions
- —
Informational only. Traditional use does not mean proven effectiveness. Evidence and safety vary — check the cited sources.
What the science says
- Draba nemorosa var. hebecarpa showed moderate antitumor activity in vitro, comparable to some mushroom extracts.
- The study found that Xinyin tablets may alleviate chronic heart failure in mice by regulating the HDAC3-PINK1/Parkin signaling pathway.
- The study found that the status of the gene for ribosomal protein S16 varies among species of Arabidopsis and related genera.
- The study identified five gene families that may be involved in the life history switch from perennial to annual in plants.
- The study found that psychrotolerant bacterial isolates from cold-adapted plants improved the cold resistance of bean seedlings by reducing freezing injury and stimulating antioxidant enzyme activity.
Frequently asked questions
What is Draba nemorosa?
Draba nemorosa (Draba nemorosa) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Draba nemorosa?
5 sourced findings are recorded for Draba nemorosa; the strongest carries evidence grade D. For example: Draba nemorosa var. hebecarpa showed moderate antitumor activity in vitro, comparable to some mushroom extracts.
How strong is the evidence for Draba nemorosa?
The strongest finding for Draba nemorosa carries evidence grade D — preliminary or traditional. Grades run A (strongest) to D (preliminary or traditional).
Is Draba nemorosa safe? What are the side effects?
No major safety issues are recorded for Draba nemorosa in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Draba nemorosa interact with medications?
No drug interactions are recorded for Draba nemorosa in our sources. This does not rule them out — check with a pharmacist.
What are the common names of Draba nemorosa?
Draba nemorosa is also known as: Drave des bois.
Is Draba nemorosa a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
Sources
- T2 Different status of the gene for ribosomal protein S16 in the chloroplast genome during evolution of the genus Arabidopsis and closely related species. literature abstract metadata
- T2 Comparative antitumor activity of jelly ear culinary-medicinal mushroom, Auricularia auricula-judae (Bull.) J. Schrot. (higher basidiomycetes) extracts against tumor cells in vitro. literature abstract metadata
- T2 Pinpointing genes underlying annual/perennial transitions with comparative genomics. literature abstract metadata
- T2 Psychrotolerant bacteria isolated from the leaf apoplast of cold-adapted wild plants improve the cold resistance of bean (Phaseolus vulgaris L.) under low temperature. literature abstract metadata
- T2 Xinyin tablets affect mitophagy and cardiomyocyte apoptosis to alleviate chronic heart failure by regulating histone deacetylase 3(HDAC3)-mediated PTEN induced putative kinase 1(PINK1)/Parkin signaling pathway. literature abstract metadata